drugset / Trial / NCT01731002

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

NCT01731002

Phase 2 Completed 224 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost

Timeline

Start
2012-11
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 %
Subject Netarsudil Small molecule 0.01 %
Subject Netarsudil Small molecule 0.02 %